A Novel Temozolomide Perillyl Alcohol Conjugate Exhibits Superior Activity against Breast Cancer Cells in vitro and Intracranial Triple-Negative Tumor Growth in vivo

May 2014

Molecular Cancer Therapeutics 2014, 13:1181.


This report on compound NEO212 demonstrates its cancer therapeutic potency in cell culture and mouse models of triple-negative breast cancer, a particularly aggressive subtype of breast cancer that tends to spread and reoccur despite the best current treatments. This study finds that NEO212 is effective at killing all types of breast cancer cells, but in particular triple-negative breast cancer cells. Using a mouse model of triple-negative breast cancer that has spread to the brain, the researchers demonstrate that NEO212 also exerts therapeutic effect against this most difficult-to-treat breast cancer stage.

Comments are closed.